Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 8/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 7/20 | 0.36 |
| ▸ | DRD5 | P21918 | 7/20 | 0.36 |
| ▸ | DRD2 | P14416 | 6/20 | 0.36 |
| ▸ | DRD3 | P35462 | 6/20 | 0.36 |
| ▸ | DRD4 | P21917 | 5/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18596812 | 0.86 | HSD17B3 (0.36) | HSD17B3CYP11B1CYP11B2CYP1A2CYP17A1 | |
| SCHEMBL20905279 | 0.84 | CYP11B1 (0.50) | HSD17B3CYP11B1CYP11B2CYP1A2CYP17A1 | |
| SCHEMBL19035882 | 0.83 | DRD1 (0.37) | HSD17B3CYP1A2DRD1DRD5DRD2 | |
| SCHEMBL2616329 | 0.75 | DRD3 (0.48) | HSD17B3CYP1A2DRD1DRD5DRD2 | |
| SCHEMBL18596813 | 0.73 | CYP11B1 (0.42) | HSD17B3CYP11B1CYP11B2CYP1A2CYP17A1 | |
| SCHEMBL13615992 | 0.72 | CYP11B1 (0.43) | HSD17B3CYP11B1CYP11B2CYP1A2CYP17A1 | |
| SCHEMBL13615807 | 0.72 | CYP11B1 (0.43) | HSD17B3CYP11B1CYP11B2CYP1A2CYP17A1 | |
| SCHEMBL20625222 | 0.72 | CYP11B1 (0.41) | HSD17B3CYP11B1CYP11B2CYP1A2CYP17A1 | |
| SCHEMBL12013898 | 0.72 | HSD17B3 (0.56) | HSD17B3CYP1A2DRD1DRD5DRD2 | |
| SCHEMBL2604390 | 0.72 | MAOA (0.52) | HSD17B3CYP1A2DRD1DRD5DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091452-B2 | Polymerizable compound, polymerizable composition, polymer, optically anisotropic body, and method for producing polymerizable compound | ZEON CORPORATION (JP) | 2021-08-17 | — | — | US | disclosed |
| US-10669482-B2 | Liquid crystal composition, liquid crystal cured layer, and method for producing said liquid crystal cured layer | ZEON CORPORATION (JP) | 2020-06-02 | — | — | US | disclosed |
| US-10647920-B2 | Liquid crystalline composition, liquid crystal cured layer, method for producing same, and optical film | ZEON CORPORATION (JP) | 2020-05-12 | — | — | US | disclosed |
| US-10620352-B2 | Circularly polarized light separating film and method for producing same | ZEON CORPORATION (JP) | 2020-04-14 | — | — | US | disclosed |
| US-20200048213-A1 | POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION, POLYMER, OPTICALLY ANISOTROPIC BODY, AND METHOD FOR PRODUCING POLYMERIZABLE COMPOUND | ZEON CORPORATION (JP) | 2020-02-13 | — | — | US | disclosed |
| US-20190225884-A1 | LIQUID CRYSTALLINE COMPOSITION, LIQUID CRYSTAL CURED LAYER, METHOD FOR PRODUCING SAME, AND OPTICAL FILM | ZEON CORPORATION (JP) | 2019-07-25 | — | — | US | disclosed |
| US-20190093014-A1 | LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL CURED LAYER, AND METHOD FOR PRODUCING SAID LIQUID CRYSTAL CURED LAYER | ZEON CORPORATION (JP) | 2019-03-28 | — | — | US | disclosed |
| US-10207474-B2 | Multilayer film, optically anisotropic layered body, circularly polarizing plate, organic electroluminescence display device, and manufacturing method | ZEON CORPORATION (JP) | 2019-02-19 | — | — | US | disclosed |
| US-20180143361-A1 | CIRCULARLY POLARIZED LIGHT SEPARATING FILM AND METHOD FOR PRODUCING SAME | ZEON CORPORATION (JP) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048213-A1 | POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION, POLYMER, OPTICALLY ANISOTROPIC BODY, AND METHOD FOR PRODUCING POLYMERIZABLE COMPOUND | PDE8A, MAPT, PLK4 | HSD17B3 1351/4885CYP11B1 3005/4885CYP11B2 3322/4885 |
| US-11091452-B2 | Polymerizable compound, polymerizable composition, polymer, optically anisotropic body, and method for producing polymerizable compound | PDE8A, MAPT, PLK4 | HSD17B3 1351/4885CYP11B1 3005/4885CYP11B2 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.